p73 and p63: Why do we still need them?

Cell Cycle

Volumn 3, Issue 7, 2004, Pages 884-892

  Blandino, Giovanni ^a   Dobbelstein, Matthias ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Evolution; p53; p63; p73; Transcription

Indexed keywords

CELL PROTEIN; MESSENGER RNA; PROTEIN P53; PROTEIN P63; PROTEIN P73; TUMOR SUPPRESSOR PROTEIN;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; GENE DELETION; GENE EXPRESSION REGULATION; GENE TARGETING; GENOME; PHYLOGENY; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; TRANSACTIVATION;

EID: 13144295009     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.7.996     Document Type: Review

References (150)

1. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2:594-604.
2. Schmale H, Bamberger C. A novel protein with strong homology to the tumor suppressor p53. Oncogene 1997; 15:1363-7.
3. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90:809-19.
4. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2:305-16.
5. Shaul Y. c-Abl: Activation and nuclear targets. Cell Death Differ 2000; 7:10-6.
6. Arrowsmith CH. Structure and function in the p53 family. Cell Death Differ 1999; 6:1169-73.
7. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: P63, p73 and the rise of p53. Trends Genet 2002; 18:90-5.
8. Kaelin Jr WG. The p53 gene family. Oncogene 1999; 18:7701-5.
9. Marin MC, Kaelin Jr WG. p63 and p73: Old members of a new family. Biochim Biophys Acta 2000; 1470:M93-M100.
10. Irwin MS, Kaelin WG. p53 family update: P73 and p63 develop their own identities. Cell Growth Differ 2001; 12:337-49.
11. Levrero M, De Laurenzi V, Costanzo A, Gong J, Melino G, Wang JY. Structure, function and regulation of p63 and p73. Cell Death Differ 1999; 6:1146-53.
12. De Laurenzi V, Melino G. Evolution of functions within the p53/p63/p73 family. Ann N Y Acad Sci 2000; 926:90-100.
13. Maisse C, Guerrieri P, Melino G. p73 and p63 protein stability: The way to regulate function? Biochem Pharmacol 2003; 66:1555-61.
14. Melino G, Lu X, Gasco M, Crook T, Knight RA. Functional regulation of p73 and p63: Development and cancer. Trends Biochem Sci 2003; 28:663-70.
15. Courtois S, de Fromentel CC, Hainaut P. p53 protein variants: Structural and functional similarities with p63 and p73 isoforms. Oncogene 2004; 23:631-8.
16. Strano S, Rossi M, Fontemaggi G, Munarriz E, Soddu S, Sacchi A, et al. From p63 to p53 across p73. FEBS Lett 2001; 490:163-70.
17. Lohrum MA, Vousden KH. Regulation and activation of p53 and its family members. Cell Death Differ 1999; 6:1162-8.
18. Stiewe T, Putzer BM. Role of p73 in malignancy: Tumor suppressor or oncogene? Cell Death Differ 2002; 9:237-45.
19. Stiewe T, Putzer BM. p73 in apoptosis. Apoptosis 2001; 6:447-52.
20. Moll UM, Erster S, Zaika A. p53, p63 and p73-solos, alliances and feuds among family members. Biochim Biophys Acta 2001; 1552:47-59.
21. Ikawa S, Nakagawara A, Ikawa Y. p53 family genes: Structural comparison, expression and mutation. Cell Death Differ 1999; 6:1154-61.
22. Soussi T. p53 mutations and resistance to chemotherapy: A stab in the back for p73. Cancer Cell 2003; 3:303-5.
23. Urist M, Prives C. p53 leans on its siblings. Cancer Cell 2002; 1:311-3.
24. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: Overlapping and distinct functions. J Cell Sci 2000; 113:1661-70.
25. Brunner HG, Hamel BC, Van Bokhoven H. The p63 gene in EEC and other syndromes. J Med Genet 2002; 39:377-81.
26. Irwin MS, Kaelin Jr WG. Role of the newer p53 family proteins in malignancy. Apoptosis 2001; 6:17-29.
27. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin Jr WG. Chemosensitivity linked to p73 function. Cancer Cell 2003; 3:403-10.
28. Kaelin Jr WG. Another p53 Doppelganger? Science 1998; 281:57-8.
29. Kaelin Jr WG. The emerging p53 gene family. J Natl Cancer Inst 1999; 91:594-8.
30. Knight RA, Candi E, Melino G. The p53 homology trap. Cancer Biol Ther 2003; 2:63-6.
31. McKeon F. p63 and the epithelial stem cell: More than status quo? Genes Dev 2004; 18:465-9.
32. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2:605-15.
33. Melino G. p73, the "assistant" guardian of the genome? Ann N Y Acad Sci 2003; 1010:9-15.
34. Oren M. Lonely no more: P53 finds its kin in a tumor suppressor haven. Cell 1997; 90:829-32.
35. van Bokhoven H, Brunner HG. Splitting p63. Am J Hum Genet 2002; 71:1-13.
36. White E, Prives C. DNA damage enables p73. Nature 1999; 399:734-5, 737.
37. Yang A, McKeon F. p63 and p73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000; 1:199-207.
38. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 1998; 58:1380-3.
39. Sunahara M, Ichimiya S, Nimura Y, Takada N, Sakiyama S, Sato Y, et al. Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. Int J Oncol 1998; 13:319-23.
40. Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, et al. Mutation allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res 1998; 58:2076-7.
41. Dobbelstein M, Roth J. The large T antigen of simian virus 40 binds and inactivates p53 but not p73. J Gen Virol 1998; 79:3079-83.
42. Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin Jr WG. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 1998; 18:6316-24.
43. Prabhu NS, Somasundaram K, Saryamoorthy K, Herlyn M, El-Deiry WS. p73, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int J Oncol 1998; 13:5-9.
44. Reichelt M, Zang KD, Seifert M, Welter C, Ruffing T. The yeast two-hybrid system reveals no interaction between p73 α and SV40 large T-antigen. Arch Virol 1999; 144:621-6.
45. Roth J, König C, Wienzek S, Weigel S, Ristea S, Dobbelstein M. Inactivation of p53 but not p73 by adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins. J Virol 1998; 72:8510-8516.
46. Roth J, Dobbelstein M. Failure of viral oncoproteins to target the p53-homologue p51A. J Gen Virol 1999; 80:3251-5.
47. Steegenga WT, Shvarts A, Riteco N, Bos JL, Jochemsen AG. Distinct regulation of p53 and p73 activity by adenovirus E1A, E1B, and e4orf6 proteins. Mol Cell Biol 1999; 19:3885-94.
48. Wienzek S, Roth J, Dobbelstein M. E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53. J Virol 2000; 74:193-202.
49. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21.
50. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404:99-103.
51. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-8.
52. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992; 71:875-86.
53. Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J, Dobbelstein M. p53 induces the expression of its antagonist p73 ΔN, establishing an autoregulatory feedback loop. Oncogene 2002; 21:4715-27.
54. Klein C, Georges G, Kunkele KP, Huber R, Engh RA, Hansen S. High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53. J Biol Chem 2001; 276:37390-401.
55. Stiewe T, Theseling CC, Putzer BM. Transactivation-deficient ΔTA-p73 inhibits p53 by direct competition for DNA-binding: Implications for tumorigenesis. J Biol Chem 2002; 13:13.
56. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. Transactivation-deficient ΔTA-p73 acts as an oncogene. Cancer Res 2002; 62:3598-602.
57. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Putzer BM. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 2004; 10:626-33.
58. Courrois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U, et al. ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002; 21:6722-8.
59. Marston NJ, Ludwig RL, Vousden KH. Activation of p53 DNA binding activity by point mutation. Oncogene 1998; 16:3123-31.
60. Kim CA, Bowie JU. SAM domains: Uniform structure, diversity of function. Trends Biochem Sci 2003; 28:625-8.
61. McGrath JA, Duijf PH, Doetsch V, Irvine AD, de Waal R, Vanmolkot KR, et al. Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum Mol Genet 2001; 10:221-9.
62. van Bokhoven H, McKeon F. Mutations in the p53 homolog p63: Allele-speciftc developmental syndromes in humans. Trends Mol Med 2002; 8:133-9.
63. Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L. Complex transcriptional effects of p63 isoforms: Identification of novel activation and repression domains. Mol Cell Biol 2002; 22:8659-68.
64. Pestka S. A dance between interferon-α/β and p53 demonstrates collaborations in tumor suppression and antiviral activities. Cancer Cell 2003; 4:85-7.
65. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424:516-23.
66. Seelan RS, Irwin M, van der Stoop P, Qian C, Kaelin Jr WG, Liu W. The human p73 promoter: Characterization and identification of functional E2F binding sites. Neoplasia 2002; 4:195-203.
67. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000; 407:645-8.
68. Stiewe T, Putzer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000; 26:464-9.
69. Zaika A, Irwin M, Sansome C, Moll UM. Oncogenes induce and activate endogenous p73 protein. J Biol Chem 2001; 276:11310-6.
70. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, et al. Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001; 8:1213-23.
71. Nakagawa T, Takahashi M, Ozaki T, Watanabe Ki K, Todo S, Mizuguchi H, et al. Auto inhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. Mol Cell Biol 2002; 22:2575-85.
72. Waltermann A, Kartasheva NN, Dobbelstein M. Differential regulation of p63 and p73 expression. Oncogene 2003; 22:5686-93.
73. Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G, et al. The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol Cell Biol 2001; 21:8461-70.
74. Arai N, Nomura D, Yokota K, Wolf D, Brill E, Shohat O, et al. Immunologically distinct p53 molecules generated by alternative splicing. Mol Cell Biol 1986; 6:3232-9.
75. Wu L, Bayle JH, Elenbaas B, Pavlerich NP, Levine AJ. Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol Cell Biol 1995; 15:497-504.
76. Bayle JH, Elenbaas B, Levine AJ. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc Natl Acad Sci USA 1995; 92:5729-33.
77. Zwahlen D, Tschan MP, Grob TJ, Peters UR, Fink D, Haenggi W, et al. Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours. Int J Cancer 2000; 88:66-70.
78. Zaika AI, Kovalev S, Marchenko ND, Moll UM. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 1999; 59:3257-63.
79. Pagani F, Baralle FE. Genomic variants in exons and introns. Identifying the splicing spoilers. Nat Rev Genetics 2004; 5:389-96.
80. Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH. Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol 1994; 1:877-90.
81. Davison TS, Vagner C, Kaghad M, Ayed A, Caput D, Arrowsmith CH. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem 1999; 274:18709-14.
82. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25:47-54.
83. Strano S, Blandino G. p73-mediated chemosensitivity: A preferential target of oncogenic mutant p53. Cell Cycle 2003; 2:348-9.
84. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 2002; 277:18817-26.
85. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 2000; 275:29503-12.
86. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416:560-4.
87. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000; 242:15-29.
88. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274:948-53.
89. Balint E, Bates S, Vousden KH. Mdm2 binds p73 α without targeting degradation. Oncogene 1999; 18:3923-9.
90. Dobbelstein M, Wienzek S, König C, Roth J. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 1999; 18:2101-6.
91. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 1999; 19:3257-66.
92. Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem 2002; 277:2674-81.
93. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001; 276:15164-73.
94. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11:11-23.
95. Roth J, Lenz-Bauer C, Contente A, Lohr K, Koch P, Bernard S, et al. Reactivation of mutant p53 by a one-hybrid adaptor protein. Cancer Res 2003; 63:3904-8.
96. Higashino F, Pipas JM, Shenk T. Adenovirus e4orf6 oncoprotein modulates the function of the p53-related protein, p73. Proc Natl Acad Sci USA 1998; 95:15683-7.
97. Querido E, Morrison MR, Chu-Pham-Dang H, Thirlwell SW, Boivin D, Branton PE, et al. Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. J Virol 2001; 75:699-709.
98. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ 2003; 10:400-3.
99. Oren M. Decision making by p53: Life, death and cancer. Cell Death Differ 2003; 10:431-42.
100. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Curr Opin Cell Biol 2003; 15:164-71.
101. Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature 1999; 399:809-13.
102. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399:806-9.
103. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399:814-7.
104. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 2002; 9:175-86.
105. Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S, et al. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem 2002; 277:43359-68.
106. Okada Y, Osada M, Kurata S, Sato S, Aisaki K, Kageyama Y, et al. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63α) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation. Exp Cell Res 2002; 276:194-200.
107. Katoh I, Aisaki KI, Kurata SI, Ikawa S, Ikawa Y. p51A (TAp63γ), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene 2000; 19:3126-30.
108. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999; 19:1438-49.
109. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 3:387-402.
110. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001; 21:1874-87.
111. Gonzalez S, Prives C, Cordon-Cardo C. p73α regulation by Chk1 in response to DNA damage. Mol Cell Biol 2003; 23:8161-71.
112. Fulco M, Costanzo A, Merlo P, Mangiacasale R, Strano S, Blandino G, et al. p73 is regulated by phosphorylation at the G2/M transition. J Biol Chem 2003; 278:49196-202.
113. Gaiddon C, Lokshin M, Gross I, Levasseur D, Taya Y, Loeffler JP, et al. Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J Biol Chem 2003; 278:27421-31.
114. Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R, et al. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol Cell 2004; In Press.
115. Prives C, Manley JL. Why is p53 acetylated? Cell 2001; 107:815-8.
116. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor. One gene-two products-two pathways. Trends Biochem Sci 1998; 23:291-6.
117. Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 2003; 23:8902-12.
118. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003; 3:577-87.
119. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT. SUMO-1 modification activates the transcriptional response of p53. Embo J 1999; 18:6455-61.
120. Minty A, Dumont X, Kaghad M, Caput D. Covalent modification of p73α by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 2000; 275:36316-23.
121. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1:45-9.
122. Zauberman A, Barak Y, Ragimov N, Levy N, Oren M. Sequence-specific DNA binding by p53: Identification of target sites and lack of binding to p53 - MDM2 complexes. EMBO J 1993; 12:2799-808.
123. KIP2 expression by p73β. Proc Natl Acad Sci USA 2002; 99:3529-34.
124. Kartasheva NN, Lenz-Bauer C, Hartmann, Schäfer H, Eilers M, Dobbelstein M. ΔNp73 can modulate the expression of various genes in a p53-independent fashion. Oncogene 2003; In Press.
125. Stiewe T, Stanelle J, Theseling CC, Pollmeier B, Beitzinger M, Putzer BM. Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73. J Biol Chem 2003; 278:14230-6.
126. Clevers H. Wnt breakers in colon cancer. Cancer Cell 2004; 5:5-6.
127. Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R, et al. ΔNp63 induces β-catenin nuclear accumulation and signaling. Cancer Cell 2002; 1:369-79.
128. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 2004; 18:126-31.
129. Koster MI, Roop DR. Transgenic mouse models provide new insights into the role of p63 in epidermal development. Cell Cycle 2004; 3:411-3.
130. Barrow LL, van Bokhoven H, Daack-Hirsch S, Andersen T, van Beersum SE, Gorlin R, et al. Analysis of the p63 gene in classical EEC syndrome, related syndromes, and nonsyndromic orofacial clefts. J Med Genet 2002; 39:559-66.
131. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 1999; 99:143-53.
132. Duijf PH, Vanmolkot KR, Propping P, Friedl W, Krieger E, McKeon F, et al. Gain-of-function mutation in ADULT syndrome reveals the presence of a second transactivation domain in p63. Hum Mol Genet 2002; 11:799-804.
133. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 2002; 10:995-1005.
134. Giltay JC, Wittebol-Post D, van Bokhoven H, Kastrop PM, Lock MT. Split hand/split foot, iris/choroid coloboma, hypospadias and subfertility: A new developmental malformation syndrome? Clin Dysmorphol 2002; 11:231-5.
135. van Bokhoven H, Hamel BC, Bamshad M, Sangiorgi E, Gurrieri F, Duijf PH, et al. p63 Gene mutations in eec syndrome limb-mammary syndrome, and isolated split hand-split foot malformation suggest a genotype-phenotype correlation. Am J Hum Genet 2001; 69:481-92.
136. Witters I, Van Bokhoven H, Goossens A, Van Assche FA, Fryns JP. Split-hand/split-foot malformation with paternal mutation in the p63 gene. Prenat Diagn 2001; 21:1119-22.
137. Kovalev S, Marchenko N, Swendeman S, LaQuaglia M, Moll UM. Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ 1998; 9:897-903.
138. Hagiwara K, McMenamin MG, Miura K, Harris CC. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res 1999; 59:4165-9.
139. Nishi H, Isaka K, Sagawa Y, Usuda S, Fujito A, Ito H, et al. Mutation and transcription analyses of the p63 gene in cervical carcinoma. Int J Oncol 1999; 15:1149-53.
140. Yokomizo A, Mai M, Bostwick DG, Tindall DJ, Qian J, Cheng L, et al. Mutation and expression analysis of the p73 gene in prostate cancer. Prostate 1999; 39:94-100.
141. Douc-Rasy S, Barrels M, Echeynne M, Kaghad M, Blanc E, Raguenez G, et al. ΔN-p73α accumulates in human neuroblastic tumors. Am J Pathol 2002; 160:631-9.
142. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, et al. Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002; 9:246-51.
143. Dominguez G, Silva JM, Silva J, Garcia JM, Sanchez A, Navarro A, et al. Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast Cancer Res Treat 2001; 66:183-90.
144. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, et al. Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004; 64:2449-60.
145. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000; 97:5462-7.
146. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11:577-90.
147. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004; 6:443-50.
148. Dumont P, Leu JI, Della Pietra III AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-65.
149. Campisi J. Cellular senescence and apoptosis: How cellular responses might influence aging phenotypes. Exp Gerontol 2003; 38:5-11.
150. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, et al. ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002; 196:765-80.